Operating Segments

3 Months Ended

Mar. 31, 2022

Operating Segments

Operating Segments

Note 10. Operating Segments

The Company maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended
	March 31,
	2022		2021
Revenues
Specialized BioTherapeutics	$	—	$	—
Public Health Solutions		188,063		147,593
Total	$	188,063	$	147,593
Loss from Operations
Specialized BioTherapeutics	$	(1,539,728)	$	(1,112,408)
Public Health Solutions		(120,621)		(130,781)
Corporate		(2,542,279)		(990,418)
Total	$	(4,202,628)	$	(2,233,607)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	2,614	$	1,899
Public Health Solutions		436		316
Corporate		5,182		6,684
Total	$	8,232	$	8,899
Other (Expense)/Income, Net
Specialized BioTherapeutics	$	55,079	$	84,634
Corporate		(201,472)		(213,505)
Total	$	(146,393)	$	(128,871)
Share-Based Compensation
Specialized BioTherapeutics	$	28,504	$	29,579
Public Health Solutions		1,054		6,295
Corporate		48,713		58,931
Total	$	78,271	$	94,805

	As of		As of
	March 31,		December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	223,895	$	128,645
Public Health Solutions		132,921		146,296
Corporate		23,317,828		26,594,986
Total	$	23,674,644	$	26,869,927